[go: up one dir, main page]

WO2019113375A3 - Dosing regimens for the mobilization of hematopoietic stem and progenitor cells - Google Patents

Dosing regimens for the mobilization of hematopoietic stem and progenitor cells Download PDF

Info

Publication number
WO2019113375A3
WO2019113375A3 PCT/US2018/064335 US2018064335W WO2019113375A3 WO 2019113375 A3 WO2019113375 A3 WO 2019113375A3 US 2018064335 W US2018064335 W US 2018064335W WO 2019113375 A3 WO2019113375 A3 WO 2019113375A3
Authority
WO
WIPO (PCT)
Prior art keywords
progenitor cells
hematopoietic stem
mobilization
cells
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/064335
Other languages
French (fr)
Other versions
WO2019113375A2 (en
Inventor
Dwight Morrow
Patrick C. Falahee
Anthony Boitano
Michael P. Cooke
Kevin A. GONCALVES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianthus Therapeutics Inc
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/834,017 external-priority patent/US10058573B1/en
Priority to CN201880088815.6A priority Critical patent/CN111712262A/en
Priority to JP2020531468A priority patent/JP2021505172A/en
Priority to IL275077A priority patent/IL275077B2/en
Priority to EP18829615.6A priority patent/EP3720494A2/en
Priority to MX2020005878A priority patent/MX2020005878A/en
Priority to BR112020011186-4A priority patent/BR112020011186A2/en
Priority to IL315735A priority patent/IL315735A/en
Priority to EA202091092A priority patent/EA202091092A1/en
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Priority to SG11202004913TA priority patent/SG11202004913TA/en
Priority to AU2018378804A priority patent/AU2018378804B2/en
Priority to KR1020207019222A priority patent/KR20200096942A/en
Priority to CA3083783A priority patent/CA3083783A1/en
Priority to US16/352,578 priority patent/US11260079B2/en
Publication of WO2019113375A2 publication Critical patent/WO2019113375A2/en
Publication of WO2019113375A3 publication Critical patent/WO2019113375A3/en
Anticipated expiration legal-status Critical
Priority to CONC2020/0007275A priority patent/CO2020007275A2/en
Priority to JP2023188499A priority patent/JP2024023226A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)

Abstract

The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft vs. host disease.
PCT/US2018/064335 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells Ceased WO2019113375A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AU2018378804A AU2018378804B2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
JP2020531468A JP2021505172A (en) 2017-12-06 2018-12-06 Dosing regimen to mobilize hematopoietic stem cells and progenitor cells
IL275077A IL275077B2 (en) 2017-12-06 2018-12-06 Dosing Regimens for the Mobilization of Hematopoietic Stem and Progenitor Cells
EP18829615.6A EP3720494A2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
MX2020005878A MX2020005878A (en) 2017-12-06 2018-12-06 DOSAGE GUIDELINES FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS.
BR112020011186-4A BR112020011186A2 (en) 2017-12-06 2018-12-06 dosing regimens for stem cell mobilization and hematopoietic progenitors
IL315735A IL315735A (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of stem cells and hematopoietic progenitor cells
EA202091092A EA202091092A1 (en) 2018-11-30 2018-12-06 DOSED ADMINISTRATION SCHEME FOR MOBILIZATION OF HEMOPOETIC STEM CELLS AND PRECURSOR CELLS
SG11202004913TA SG11202004913TA (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN201880088815.6A CN111712262A (en) 2017-12-06 2018-12-06 Dosing regimen for mobilization of hematopoietic stem and progenitor cells
CA3083783A CA3083783A1 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
KR1020207019222A KR20200096942A (en) 2017-12-06 2018-12-06 Dosing regimen for mobilization of hematopoietic stem and progeny cells
US16/352,578 US11260079B2 (en) 2017-12-06 2019-03-13 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CONC2020/0007275A CO2020007275A2 (en) 2017-12-06 2020-06-16 Dosage guidelines for mobilization of hematopoietic stem and progenitor cells
JP2023188499A JP2024023226A (en) 2017-12-06 2023-11-02 Dosing regimen to mobilize hematopoietic stem and progenitor cells

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US15/834,017 2017-12-06
US15/834,017 US10058573B1 (en) 2017-12-06 2017-12-06 Dosing regimens for the mobilization of hematopoietic stem cells
US201762596056P 2017-12-07 2017-12-07
US62/596,056 2017-12-07
US16/101,676 US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells
US16/101,676 2018-08-13
US201862753656P 2018-10-31 2018-10-31
US62/753,656 2018-10-31
US201862773954P 2018-11-30 2018-11-30
US62/773,954 2018-11-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/101,676 Continuation-In-Part US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/352,578 Continuation US11260079B2 (en) 2017-12-06 2019-03-13 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Publications (2)

Publication Number Publication Date
WO2019113375A2 WO2019113375A2 (en) 2019-06-13
WO2019113375A3 true WO2019113375A3 (en) 2019-07-18

Family

ID=66749948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/064335 Ceased WO2019113375A2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Country Status (12)

Country Link
EP (1) EP3720494A2 (en)
JP (2) JP2021505172A (en)
KR (1) KR20200096942A (en)
CN (1) CN111712262A (en)
AU (1) AU2018378804B2 (en)
BR (1) BR112020011186A2 (en)
CA (1) CA3083783A1 (en)
CO (1) CO2020007275A2 (en)
IL (2) IL275077B2 (en)
MX (2) MX2020005878A (en)
SG (1) SG11202004913TA (en)
WO (1) WO2019113375A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
EP4051298A1 (en) * 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
CA3176979A1 (en) * 2020-04-27 2021-11-04 Anthony Boitano Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) * 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
KR20250023521A (en) * 2022-06-10 2025-02-18 주식회사 지피씨알 GPCR inhibitors and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000333A1 (en) * 2003-06-05 2005-01-06 Anormed Inc. Methods to mobilize progenitor/stem cells
US20060035829A1 (en) * 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2007047882A2 (en) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combination of cxcr4 antagonist and morphogen to increase angiogenesis
WO2008017025A2 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
WO2008019371A1 (en) * 2006-08-07 2008-02-14 Genzyme Corporation Combination therapy
WO2017147610A1 (en) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Highly engraftable hematopoietic stem cells
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5233044A (en) 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
ES2284161T3 (en) 1990-01-12 2007-11-01 Amgen Fremont Inc. GENERATION OF XENOGENIC ANTIBODIES.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2341666T3 (en) 1991-12-02 2010-06-24 Medimmune Limited PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE.
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
ATE253637T1 (en) 1993-06-08 2003-11-15 Smithkline Beecham Corp METHODS OF INCREASE THE BIOLOGICAL ACTIVITY OF CHEMOKINES
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
DK0909176T3 (en) 1997-02-11 2003-02-17 Mallinckrodt Inc Reactor and method for solid phase peptide synthesis
CA2731416A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
MXPA01009674A (en) 1999-03-24 2003-07-21 Anormed Inc Chemokine recpetor binding heterocyclic compounds.
AU2334301A (en) 1999-12-17 2001-06-25 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AU2001258110B2 (en) 2000-05-09 2006-10-19 British Canadian Biosciences Corp. Cxcr4 antagonist treatment of hematopoietic cells
US20040131585A1 (en) 2000-06-05 2004-07-08 Silviu Itescu Identification and use og human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
MXPA04000982A (en) * 2001-07-31 2004-04-20 Anormed Inc Methods to mobilize progenitor/stem cells.
CA2456977C (en) 2001-08-16 2011-06-07 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMER COMPOUNDS AND COMPOSITIONS FOR USE IN THE MODULATION OF SMALL NON-CODING RNAS
AU2006262020B8 (en) 2005-06-24 2011-02-17 Recombinetics, Inc. Using cytosine deaminases to diminish retroelement transfer from pigs to humans
CA3055968A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
EP1995316A1 (en) 2007-05-25 2008-11-26 Qiagen GmbH Method for gentle purification of cells, cell production and cell transfection
EP2009095A1 (en) 2007-06-28 2008-12-31 Innovalor AG Method of generating glucose-responsive cells
EP3578646A3 (en) 2007-10-31 2020-03-18 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
PE20100362A1 (en) 2008-10-30 2010-05-27 Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
EP2270025A1 (en) 2009-06-29 2011-01-05 Centre National pour la Recherche Scientifique (CNRS) Solid phase peptide synthesis of peptide alcohols
WO2011100505A2 (en) 2010-02-11 2011-08-18 Recombinetics, Inc. Methods and materials for producing transgenic artiodactyls
EA201391234A1 (en) 2011-02-25 2014-05-30 Рикомбинетикс, Инк. GENETICALLY MODIFIED ANIMALS AND METHODS OF THEIR RECEIVING
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014113439A1 (en) * 2013-01-15 2014-07-24 Ohio State Innovation Foundation Methods for mobilizing hematopoietic stem cells
KR20160023638A (en) * 2013-02-28 2016-03-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Methods and compositions for mobilizing stem cells
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000333A1 (en) * 2003-06-05 2005-01-06 Anormed Inc. Methods to mobilize progenitor/stem cells
US20060035829A1 (en) * 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2007047882A2 (en) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combination of cxcr4 antagonist and morphogen to increase angiogenesis
WO2008017025A2 (en) * 2006-08-02 2008-02-07 Genzyme Corporation Combination therapy
WO2008019371A1 (en) * 2006-08-07 2008-02-14 Genzyme Corporation Combination therapy
WO2017147610A1 (en) * 2016-02-26 2017-08-31 President And Fellows Of Harvard College Highly engraftable hematopoietic stem cells
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FALAHEE PATRICK C ET AL: "The Combination of GRObeta and AMD3100 Leads to Rapid and Robust Mobilization of Hematopoietic Stem Cells in Nonhuman Primates", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 130, no. Suppl. 1, 7 December 2017 (2017-12-07), pages 1920, XP009512209, ISSN: 0006-4971 *
HOGGATT JONATHAN ET AL: "Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell", CELL,, vol. 172, no. 1, 7 December 2017 (2017-12-07), pages 191, XP085336458, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2017.11.003 *
LOUIS M. PELUS: "Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand", PMC ( NIH PUBLIC ACCESS AUTHOR MANUSCRIPT), 13 January 2010 (2010-01-13), pages 1 - 16, XP055506996 *
PELUS LOUIS M ET AL: "The Combination of AMD3100 Plus GRObeta Rapidly Mobilizes Hematopoietic Stem Cells with Enhanced Homing, Adhesion and Survival Properties", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 31 October 2008 (2008-10-31), pages 71, XP009512206, ISSN: 0006-4971 *
PELUS LOUIS M ET AL: "The CXCR4 antagonist AMD3100 and the CXCR2 agonist GRO beta synergistically mobilize hematopoetic stem cells (HSC) with short and long term repopulating activity", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11, Part 1, 1 November 2006 (2006-11-01), pages 105A, XP002593607, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
MX2020005878A (en) 2020-10-07
IL315735A (en) 2024-11-01
JP2024023226A (en) 2024-02-21
EP3720494A2 (en) 2020-10-14
BR112020011186A2 (en) 2020-11-17
CO2020007275A2 (en) 2020-07-31
WO2019113375A2 (en) 2019-06-13
IL275077B2 (en) 2025-02-01
SG11202004913TA (en) 2020-06-29
IL275077A (en) 2020-07-30
IL275077B1 (en) 2024-10-01
JP2021505172A (en) 2021-02-18
CA3083783A1 (en) 2019-06-13
MX2024004652A (en) 2024-05-07
CN111712262A (en) 2020-09-25
AU2018378804B2 (en) 2025-10-02
KR20200096942A (en) 2020-08-14
AU2018378804A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
WO2019113375A3 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
MX2020005849A (en) Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof.
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
WO2019094642A8 (en) T cell manufacturing compositions and methods
CO2019013001A2 (en) Cytokine grafted antibody proteins and methods of use in cancer treatment
MX2014009219A (en) Purinone compounds as kinase inhibitors.
BR112021021165A2 (en) Amatoxin antibody-drug conjugates and their use
CY1123343T1 (en) GENERATION OF A BANK OF MESIJYMAL STRATIFIC CELLS FROM PLUGGED MONONUCLEAR CELLS OF MULTIPLE BONE MARROW DONORS
MX2018015684A (en) Compositions and methods for the depletion of cd117+cells.
WO2014186469A3 (en) Human application of engineered chimeric antigen receptor (car) t-cells
MX2017015574A (en) Inhibitors of bruton's tyrosine kinase.
MX382102B (en) Improved methods for manufacturing adoptive cell therapies
MX2017007138A (en) Methods and compositions for adoptive cell therapy.
JP2017524031A5 (en)
MX2021006932A (en) Engineered high-affinity human t cell receptors.
MX2015006268A (en) Differentiation of human fibroblast cells.
CL2020003319A1 (en) Chimeric growth factor receptors
CO2019014671A2 (en) Iarn agents for the inhibition of alpha-enac expression and methods of use
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
WO2012095743A3 (en) Adipose -derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases
WO2019217646A8 (en) Mesenchymal stromal cell exosome -treated monocytes and uses thereof
WO2019067951A3 (en) Cd1d and tcr-nkt cells
WO2019098759A3 (en) Transformed human cell and use thereof
AR108552A1 (en) MATERIALS AND METHODS TO DETERMINE OPTIMAL ADMINISTRATION REGIMES FOR THERAPEUTIC AGENTS
EP3826624A4 (en) Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3083783

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020531468

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018378804

Country of ref document: AU

Date of ref document: 20181206

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2020/0007275

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20207019222

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018829615

Country of ref document: EP

Effective date: 20200706

WWP Wipo information: published in national office

Ref document number: NC2020/0007275

Country of ref document: CO

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18829615

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020011186

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020011186

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200603

WWR Wipo information: refused in national office

Ref document number: 1020207019222

Country of ref document: KR